LumiraDx, a point of care diagnostics testing company, went public via a merger with CA Healthcare Acquisition, a special purpose acquisition company traded on Nasdaq, in a $3bn deal. “Ron and his management team have decades of entrepreneurial success in innovative diagnostics businesses and the LumiraDx Platform and testing menu offer healthcare providers and other customers major advantages over traditional central labs. LumiraDx has a clear strategy for addressing the large and underpenetrated testing market to increase next-generation POC market share. In the near-term, demand for fast, low-cost Covid-19 tests is driving strong and transformational growth for LumiraDx’s solutions,” Larry Neiterman, CAHC Chairman and CEO.